Abortion Drug Dangers EXPOSED — FDA Hid This

(LibertySociety.com) – Christiane Emery warns that the party unable to define a woman lacks credibility to control access to risky chemical abortion drugs, igniting debates on women’s safety and ideological competence.

Story Snapshot

Emery’s statement links Democrats’ gender ideology struggles to push for lax mifepristone regulations, amid GOP-led safety reviews.
Senate Republicans, including Hawley and Cassidy, expose dangers of mail-order abortion pills after FDA loosened safeguards.
HHS Secretary Robert F. Kennedy Jr. launched a mifepristone review in early 2026, backed by new House and Senate bills.
Family Research Council filed a Supreme Court brief on May 8 supporting Louisiana’s restrictions on abortion drugs.
Research shows 11-22 times higher adverse events than FDA admits, raising alarms over hemorrhage and other risks to women.

Emery’s Provocative Critique

Christiane Emery stated that the party unable to define a woman should not dictate chemical abortion access. Her comment references viral moments like UK Labour leader Keir Starmer’s 2022 evasion and U.S. echoes in Ketanji Brown Jackson’s Supreme Court hearing. Emery ties this to ongoing fights over mifepristone, arguing ideological confusion disqualifies oversight of drugs with proven risks. Republicans amplify her view, positioning themselves as women’s health defenders against FDA overreach.

Chemical Abortion Drugs’ Risky History

Mifepristone gained FDA approval in 2000 with strict protocols for abortions up to 10 weeks, paired with misoprostol in 63% of U.S. cases. The FDA eased rules in 2016, 2021, and 2023, enabling mail-order after Dobbs overturned Roe. This ended in-person safeguards from 2011-2016, despite hemorrhage risks in 1-4% of severe cases. Post-Dobbs, 14 states ban most abortions, but interstate shipping circumvents bans, prompting GOP action.

CHRISTIANE EMERY: The party that can't define what a woman is must not have the final say on chemical abortion accesshttps://t.co/78BAlgNM79

— Human Events (@HumanEvents) May 12, 2026

GOP Legislative Pushback

Senator Josh Hawley sponsored a bill demanding FDA review, citing 11% adverse events and 100% fetal lethality. Representative Mary Miller introduced the House “Restoring Safeguards Act” for in-person requirements and lawsuits against mail-order providers. Senator Bill Cassidy chaired the January 14, 2026, Senate HELP Committee hearing titled “Protecting Women: Exposing the Dangers of Chemical Abortion Drugs.” Senator Lindsey Graham criticized mail-order as undermining states’ rights.

Family Research Council filed a Supreme Court amicus brief on May 8, 2026, backing Louisiana’s laws. HHS Secretary Robert F. Kennedy Jr. announced a review in early 2026. Senate Republicans demand safety data from manufacturers. Democrats counter that efforts aim to ban abortion, not protect health.

Health Risks and Broader Impacts

EPPC analysis from 2017-2023 reports 865,000 adverse events, 22 times higher than FDA labels, including hemorrhages and mental health issues. FDA claims under 0.5% hospitalizations, but underreporting clouds data. Short-term, litigation rises with SCOTUS potential and midterm fodder framed as women’s safety. Long-term, reinstated safeguards could disrupt 63% of abortions, straining a $100 million market while prioritizing maternal health over convenience.